Evaluating the impact of pharmacogenomics on postoperative outcomes in cardiovascular surgery patients
Keywords:
Cardiovascular surgery, pharmacogenomics, pharmacogenetic testingAbstract
Cardiovascular disease (CVD) is the leading cause of death worldwide and is complex and mind-boggling. Overall, CVD is responsible for about one out of every four deaths. The phrase "cardiovascular disease" (CVD) often refers to a collection of fundamental, persistent abnormalities in the heart and veins that comprise the cardiovascular system. Therefore, with the correct drugs, these covering illnesses can be prevented or alleviated. Many prescriptions are commonly used since one medication is insufficient to treat a condition. Experts are forced to treat CVD aggressively due to the high rates of death and horror, which may cause severe drug reactions. At any rate, some people are unlikely to react favorably to the highest recommended dosage of the medication. Hereditary variation has been linked to the severity of illnesses such as circulatory strain and cholesterol levels, according to research on CVD.Pharmacogenomics holds potential for reducing adverse medication responses and increasing efficacy. It might significantly affect how cardiovascular disease is treated. With the creation of numerous pharmacogenetic tests over the last ten years, pharmacogenomics has evolved from the study of a single gene to genome-wide techniques. For cardiovascular pharmacogenomics to have the anticipated clinical impact, numerous obstacles must be removed. With an emphasis on adverse drug responses, pharmaceutical efficacy, recovery durations, and overall patient survival, this research paper assesses the effect of pharmacogenomics-guided treatment on postoperative outcomes.
Downloads
Metrics
References
Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA surgery. 2017 Mar 1;152(3):292-8.
Sumiati, Hendriyati P, Triayudi A, Yusta A, Syaefudin A. Classification of heart disorders using an artificial neural network approach. Journal of Internet Services and Information Security. 2024;14(2):189-201. https://doi.org/10.58346/JISIS.2024.I2.012
Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?. The pharmacogenomics journal. 2017 Oct;17(5):395-402.
Satish S, Herald AR. Fuzzy Attention U-Net Architecture Based Localization and YOLOv5 Detection for Fetal Cardiac Ultrasound Images. J Wirel Mob Netw Ubiquitous Comput. 2024;15(1):01-16. https://doi.org/10.58346/JOWUA.2024.I1.001
Rani KP, Arshad M, Sangeetha A. Pothole Detection Using YOLO (You Only Look Once) Algorithm. In2022 International Conference on Advancements in Smart, Secure and Intelligent Computing (ASSIC) 2022 Nov 19 (pp. 1-6). IEEE. https://doi.org/10.70102/IJARES/V4S1/9
Dunham WC, Weinger MB, Slagle J, Pretorius M, Shah AS, Absi TS, Shotwell MS, Beller M, Thomas E, Vnencak-Jones CL, Freundlich RE. CYP2D6 genotype-guided metoprolol therapy in cardiac surgery patients: rationale and design of the pharmacogenetic-guided metoprolol management for postoperative atrial fibrillation in cardiac surgery (PREEMPTIVE) pilot study. Journal of cardiothoracic and vascular anesthesia. 2020 Jan 1;34(1):20-8.
Perera K, Wickramasinghe S. Design Optimization of Electromagnetic Emission Systems: A TRIZ-based Approach to Enhance Efficiency and Scalability. Association Journal of Interdisciplinary Technics in Engineering Mechanics. 2024 Mar 29;2(1):31-5.
Hua ZL. Elucidating the Role of Cytochrome p450 Enzymes in Drug Metabolism and Interactions. Clinical Journal for Medicine, Health and Pharmacy. 2024 Sep 30;2(3):1-0.
Arasuraja G. Organizational change management in digital transformation: a framework for success. Global Perspectives in Management. 2024;2(2):12-21.
Peterson PE, Nicholson WT, Moyer AM, Arendt CJ, Smischney NJ, Seelhammer TG, Krecke CA, Haney RM, Yaw EJ, Chlan LL. Description of pharmacogenomic testing among patients admitted to the intensive care unit after cardiovascular surgery. Journal of Intensive Care Medicine. 2021 Oct;36(11):1281-5.
Jobson MC, Subhashini R. Importance of neuropsychological rehabilitation on retraining cognitive functioning in school-going children with congenital heart disease (CHD). International Academic Journal of Humanities. 2016;3(2):117-122.
Kukendrarajah K, Farmaki AE, Lambiase PD, Schilling R, Finan C, Schmidt AF, Providencia R. Advancing drug development for atrial fibrillation by prioritizing findings from human genetic association studies. EBioMedicine. 2024;105.
Jalali Z, Rezaie H. Analyzing the effect of dynamic organizational capabilities (organizational learning) and knowledge management in achieving the objectives of health reform plan. Human Resource Management. 2016;3(12):1-4.
Awad H, Ahmed A, Urman RD, Stoicea N, Bergese SD. Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery. Pharmacogenomics and Personalized Medicine. 2019 Jul 26:145-54.
Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, Poljakovic Z, Van Schaik RH, Patrinos GP. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015 Jan;16(2):137-48.
Roberts JD, Chalazan B, Andrade JG, Macle L, Nattel S, Tadros R. Clinical Genetic Testing for Atrial Fibrillation: Are We There Yet?. Canadian Journal of Cardiology. 2024 Mar 28.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.